Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 21, 2026, 9:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Epileptics Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Closed-loop System Using Transcranial Direct Current Stimulation (tDCS) for Epilepsy

NCT01415362
View directory record Official record
Conditions
Epilepsy, Seizures
Interventions
Transcranial Direct Current Stimulation
Device
Lead sponsor
Spaulding Rehabilitation Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 23, 2020 · Synced Sep 21, 2026, 9:52 PM EDT
Terminated Phase 3 Interventional Results available

A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures

NCT00699283
View directory record Official record
Conditions
Epilepsy
Interventions
Brivaracetam
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
16 Years to 75 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
43
States / cities
Little Rock, Arkansas • Garden Grove, California • Loma Linda, California + 40 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Sep 21, 2026, 9:52 PM EDT
Not listed Phase 2 Interventional

Catamenial Epilepsy Treatment

NCT01299870
View directory record Official record
Conditions
Epilepsy
Interventions
AED treatment plus placebo, Keishibukuryogan
Drug
Lead sponsor
Timothy Welty, PharmD
Other
Eligibility
21 Years to 45 Years · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 13, 2012 · Synced Sep 21, 2026, 9:52 PM EDT
Completed Phase 2 Interventional Results available

A Pilot Study To Evaluate The Effects of Everolimus on Brain mTOR Activity and Cortical Hyperexcitability in TSC and FCD

NCT02451696
View directory record Official record
Conditions
Epilepsy, Tuberous Sclerosis Complex, Focal Cortical Dysplasia
Interventions
Everolimus
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
2 Years to 40 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 31, 2021 · Synced Sep 21, 2026, 9:52 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Computerized Cognitive Training in Epilepsy

NCT02726191
View directory record Official record
Conditions
Epilepsy
Interventions
Spatial Match Exercise, Temporal Sequence Reconstruction Exercise, Token Task Exercise, Story Recall Exercise, Sample-Match (Within Modality) Exercise, Pair-Match (Across-Modality) Exercise, Triad-FiguresExercise, Monster Garden Exercise, Memory Match Exercise, Memory Matrix Exercise, Familiar Faces Exercises, Lost in Migration Exercise, Playing Koi Exercise
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 17, 2017 · Synced Sep 21, 2026, 9:52 PM EDT
Completed Not applicable Interventional Results available

Efficacy of Fluoxetine in Reducing Ictal Hypoventilation in Patients With Partial Epilepsy

NCT00986310
View directory record Official record
Conditions
Uncontrolled Partial Epilepsy, Ictal Hypoventilation
Interventions
Fluoxetine, Placebo
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Sep 21, 2026, 9:52 PM EDT
Completed No phase listed Observational

RNS® System Epilepsy Post-Approval Study

NCT02403843
View directory record Official record
Conditions
Epilepsy
Interventions
RNS System
Device
Lead sponsor
NeuroPace
Industry
Eligibility
18 Years and older
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
35
States / cities
Birmingham, Alabama • Irvine, California • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Sep 21, 2026, 9:52 PM EDT
Completed Phase 3 Interventional Results available

Safety and Tolerability of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Epilepsy

NCT00908349
View directory record Official record
Conditions
Partial Epilepsy
Interventions
Oxcarbazepine XR
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 66 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
20
States / cities
Huntsville, Alabama • Northport, Alabama • Phoenix, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Sep 21, 2026, 9:52 PM EDT
Active, not recruiting Phase 3 Interventional

Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures

NCT05067634
View directory record Official record
Conditions
Partial Epilepsy
Interventions
Xcopri
Drug
Lead sponsor
SK Life Science, Inc.
Industry
Eligibility
2 Years to 18 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
14
States / cities
Phoenix, Arizona • Palo Alto, California • Hartford, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 21, 2026, 9:52 PM EDT
Completed Phase 4 Interventional Results available

Randomized Controlled Trial to Assess Effects of Lacosamide on Sleep and Wake in Adults With Focal Epilepsy

NCT01190098
View directory record Official record
Conditions
Partial Epilepsy
Interventions
Lacosamide, Placebo
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 4, 2016 · Synced Sep 21, 2026, 9:52 PM EDT
Completed Phase 3 Interventional Results available

Open-Label Extension Study Of Safety And Tolerability Of Pregabalin In Pediatric Patients With Partial-Onset Seizures

NCT00448916
View directory record Official record
Conditions
Epilepsies, Partial
Interventions
Pregabalin
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
1 Month to 16 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
16
States / cities
Mobile, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2021 · Synced Sep 21, 2026, 9:52 PM EDT
Recruiting Not applicable Interventional

Neural Mechanisms of Spatial Representations Beyond the Self

NCT05406349
View directory record Official record
Conditions
Epilepsy Intractable
Interventions
Self-navigation task, Observation task
Behavioral
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 26, 2026 · Synced Sep 21, 2026, 9:52 PM EDT
Completed Not applicable Interventional

A Pragmatic Trial of HOBSCOTCH in Georgia

NCT04639206
View directory record Official record
Conditions
Epilepsy
Interventions
HOBSCOTCH
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Sep 21, 2026, 9:52 PM EDT
Completed No phase listed Observational

Electrical Brain Stimulation to Reduce Epileptic Seizures

NCT00344877
View directory record Official record
Conditions
Temporal Lobe Epilepsy
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 80 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 21, 2026, 9:52 PM EDT
Completed Phase 2 Interventional

Pediatric Epilepsy Trial in Subjects 1-24 Months

NCT00043875
View directory record Official record
Conditions
Epilepsy
Interventions
lamotrigine
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
1 Month to 24 Months
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
34
States / cities
Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2016 · Synced Sep 21, 2026, 9:52 PM EDT
Completed Phase 2 Interventional

Pediatric Switch Study for Children and Adolescent Patients With Epilepsy

NCT00646711
View directory record Official record
Conditions
Pediatric Epilepsy
Interventions
Depakote Delayed-Release/Depakote Sprinkle, Depakote ER
Drug
Lead sponsor
Abbott
Industry
Eligibility
6 Years to 17 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 27, 2008 · Synced Sep 21, 2026, 9:52 PM EDT
Terminated Phase 2 Interventional Results available

Buspirone Therapy for Localized Epilepsy

NCT01496612
View directory record Official record
Conditions
Anxiety Disorder, Seizures, Epilepsy, Partial Epilepsy, Depression
Interventions
Buspirone, Placebo
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 4, 2021 · Synced Sep 21, 2026, 9:52 PM EDT
Completed Not applicable Interventional

Comparison of Immediate vs Gradual Switch to Divalproex in Adults With Intellectual Disability

NCT00347152
View directory record Official record
Conditions
Epilepsy
Interventions
Divalproex
Drug
Lead sponsor
University of Kansas
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 11, 2008 · Synced Sep 21, 2026, 9:52 PM EDT
Completed Not applicable Interventional

Behavioral and Educational Tools to Improve Epilepsy Care

NCT02646631
View directory record Official record
Conditions
Epilepsy
Interventions
Usual Care, Management of Risks in Epilepsy (MORE), Telephone-based motivational interviewing (MORE+MI), Educational Materials
Other · Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 23, 2018 · Synced Sep 21, 2026, 9:52 PM EDT
Terminated Not applicable Interventional

RNS System RESPONSE Study

NCT04839601
View directory record Official record
Conditions
Epilepsy, Partial Seizure, Neurostimulator; Complications, Drug Resistant Epilepsy, Focal Epilepsy
Interventions
RNS System
Device
Lead sponsor
NeuroPace
Industry
Eligibility
12 Years to 17 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
Grand Rapids, Michigan • Hawthorne, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Sep 21, 2026, 9:52 PM EDT
Completed Phase 2 Interventional

Study of an External Responsive Neurostimulator System on Epileptiform Activity

NCT00158067
View directory record Official record
Conditions
Epilepsy
Interventions
external Responsive Neurostimulator (eRNS) System
Device
Lead sponsor
NeuroPace
Industry
Eligibility
12 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
5
States / cities
Scottsdale, Arizona • Augusta, Georgia • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2010 · Synced Sep 21, 2026, 9:52 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Comparison of the Cognitive and Behavioral Effects of Eslicarbazepine Acetate and Carbamazepine in Healthy Adults

NCT02912364
View directory record Official record
Conditions
Epilepsy
Interventions
Eslicarbazepine, Carbamazepine
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 55 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2019 · Synced Sep 21, 2026, 9:52 PM EDT
Completed Phase 3 Interventional Results available

A Study to Test the Long-term Safety, Tolerability and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

NCT05109234
View directory record Official record
Conditions
Childhood Absence Epilepsy, Juvenile Absence Epilepsy
Interventions
Brivaracetam Film-coated tablet, Brivaracetam oral solution
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
2 Years to 26 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
5
States / cities
Birmingham, Alabama • Orange, California • Augusta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Sep 21, 2026, 9:52 PM EDT
Completed Phase 1Phase 2 Interventional

Evaluation of the Pharmacokinetics, Safety, and Tolerability of TPM XR as Adjunctive Therapy in Pediatric Subjects With Epilepsy

NCT01284530
View directory record Official record
Conditions
Epilepsy
Interventions
TPM XR
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
4 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
10
States / cities
Sacramento, California • Loxahatchee Groves, Florida • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2016 · Synced Sep 21, 2026, 9:52 PM EDT